02/04/2015 - 22:01 SAN FRANCISCO – An investigational interleukin-23 inhibitor for moderate to severe plaque psoriasis achieved almost twice the PASI 90 response rate ... More » Visit websiteField of Interest: DermatologyCategories: CME-candidateRHEUM || Conference NewsSAN || Clinical NewsSAN || NewsRHEUM || NewsIMN || NewsIMN || DermatologyRHEUM || Psoriatic arthritisNews Feed: Internal Medicine News - Dermatology
